公开(公告)号：US20210169898A1

公开(公告)日：2021-06-10

申请号：US17094432

申请日：2020-11-10

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Mee Jean Kim ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee ,  Wilma Tamraz

IPC分类号： A61K31/565 ,  A61Q19/00 ,  A61K9/19 ,  A61P31/04 ,  A61K47/10 ,  A61K31/575 ,  A61K8/63 ,  A61P17/06 ,  A61K31/724 ,  A61K9/00 ,  A61P3/06 ,  A61K47/40 ,  A61K8/73 ,  A61P1/16 ,  C07J31/00

摘要： Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20230372361A1

公开(公告)日：2023-11-23

申请号：US18008605

申请日：2021-06-25

申请人： Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin ,  James E. Brown ,  Felix Theeuwes

IPC分类号： A61K31/575 ,  A61P29/00

CPC分类号： A61K31/575 ,  A61P29/00

摘要： Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

公开(公告)号：US20230310458A1

公开(公告)日：2023-10-05

申请号：US18115286

申请日：2023-02-28

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/575 ,  A61K31/568 ,  A61P13/12 ,  A01N1/02 ,  A61K35/12

CPC分类号： A61K31/575 ,  A61K31/568 ,  A61P13/12 ,  A01N1/0226 ,  A61K35/12

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

公开(公告)号：US20210169902A1

公开(公告)日：2021-06-10

申请号：US17072994

申请日：2020-10-16

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  WeiQi Lin ,  James E. Brown ,  Felix Theeuwes ,  Mee Jean Kim ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee ,  Huey-Ching Su ,  Wilma Tamraz

IPC分类号： A61K31/575 ,  A61P17/06 ,  A61K9/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10272097B2

公开(公告)日：2019-04-30

申请号：US15106883

申请日：2014-12-23

申请人： VIRGINIA COMMONWEALTH UNIVERSITY ,  DURECT CORPORATION

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/56 ,  A61K31/575 ,  A61K31/568 ,  A01N1/02 ,  A61K35/12

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

公开(公告)号：US20230285416A1

公开(公告)日：2023-09-14

申请号：US18008588

申请日：2021-06-25

申请人： Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin ,  James E. Brown ,  Terrence Blaschke

IPC分类号： A61K31/575 ,  A61P3/10

CPC分类号： A61K31/575 ,  A61P3/10

摘要： Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

公开(公告)号：US20230233580A1

公开(公告)日：2023-07-27

申请号：US18008585

申请日：2021-06-25

申请人： Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin

IPC分类号： A61K31/575 ,  A61P35/00

CPC分类号： A61K31/575 ,  A61P35/00

摘要： Aspects of the present disclosure include methods for treating at least one of cancer and non-cancerous transformation related to Epstein-Barr virus, such as at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma. Hierarchically organized carcinomas include, but are not limited to, pancreatic ductal adenocarcinoma, urothelial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, esophagus cancer, breast cancer, thyroid cancer, oral cancer, cervical cancer, ovarian cancer, and liver cancer. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

公开(公告)号：US20230047788A1

公开(公告)日：2023-02-16

申请号：US17852142

申请日：2022-06-28

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee

IPC分类号： A61K31/565 ,  A61P17/06 ,  A61P1/16 ,  A61P3/06 ,  A61P31/04 ,  A61K31/724 ,  A61K47/10 ,  A61Q19/00 ,  A61K8/73 ,  A61K31/575 ,  A61K9/19 ,  A61K9/00 ,  A61K47/40 ,  A61K8/63

摘要： Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20210046091A1

公开(公告)日：2021-02-18

申请号：US16983492

申请日：2020-08-03

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/575 ,  A61K31/568 ,  A61P13/12 ,  A01N1/02 ,  A61K35/12

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

公开(公告)号：US20190350945A1

公开(公告)日：2019-11-21

申请号：US16368553

申请日：2019-03-28

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/575 ,  A61P13/12 ,  A01N1/02 ,  A61K35/12 ,  A61K31/568

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).